Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Distillery Therapeutics

Cancer

January 16, 2019 1:46 PM UTC

Cell culture and mouse studies identified a naphthalenone-based Hsp90 inhibitor that could help treat glioblastoma. Screening of a small molecule library in a HeLa cell-based activity assay, followed by optimization and in vitro testing of the top hit, yielded a naphthalenone-based compound that inhibited Hsp90 with an IC50 of 29.5 nM. In a human glioblastoma cell line, the compound decreased growth and motility and increased levels of apoptotic markers compared with vehicle. In a xenograft mouse model of glioblastoma, the compound decreased tumor growth. Next steps could include testing the compound in patient-derived xenograft (PDX) mouse model of glioblastoma.

Soligenix Inc. has hypericin, a topical phototherapeutic agent that inhibits Hsp90, in Phase III testing for cutaneous T cell lymphoma (CTCL)...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article